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Specific bile acids are potent signaling molecules
that modulate metabolic pathways affecting lipid,
glucose and bile acid homeostasis, and the micro-
biota. Bile acids are synthesized from cholesterol
in the liver, and the key enzymes involved in bile
acid synthesis (Cyp7a1, Cyp8b1) are regulated tran-
scriptionally by the nuclear receptor FXR. We have
identified an FXR-regulated pathway upstream of a
transcriptional repressor that controls multiple bile
acid metabolism genes. We identify MafG as an
FXR target gene and show that hepatic MAFG over-
expression represses genes of the bile acid synthetic
pathway and modifies the biliary bile acid composi-
tion. In contrast, loss-of-function studies using
MafG+/ mice causes de-repression of the same
genes with concordant changes in biliary bile acid
levels. Finally, we identify functional MafG response
elements in bile acid metabolism genes using ChIP-
seq analysis. Our studies identify a molecular mech-
anism for the complex feedback regulation of bile
acid synthesis controlled by FXR.
INTRODUCTION
Bile acids function both as detergents that facilitate lipid absorp-
tionandas endogenous ligands that regulatemetabolic pathways
through activation of several nuclear receptors, including the
farnesoid X receptor (FXR, Nr1h4) as well as TGR5, a G protein-
coupled receptor (de Aguiar Vallim et al., 2013a). Although FXR
plays a particularly important role in maintaining bile acid homeo-
stasis, numerous studies have shown that FXR directly regulates
many genes that affect multiple metabolic cascades (de Aguiar
Vallim et al., 2013a; Evans and Mangelsdorf, 2014). Consistent
with these findings, mice lacking FXR exhibit not only dysregu-
lated bile acid metabolism, but also abnormal lipoprotein (Sinal298 Cell Metabolism 21, 298–310, February 3, 2015 ª2015 Elsevier Inet al., 2000) and glucose metabolism (Duran-Sandoval et al.,
2005; Zhang et al., 2006), increased hepatic susceptibility to
certain toxins (Lee et al., 2010), increased levels of ileal bacteria,
and impaired barrier function of intestinal epithelia (Inagaki et al.,
2006). Reduced FXR signaling is also associated with obesity,
possibly as a result of bile acid-dependent modulation of the mi-
crobiota (Li et al., 2013; Ridaura et al., 2013). Moreover, a recent
study demonstrated that in mice, the benefits of bariatric surgery
may be mediated by FXR signaling to modulate bile acid-depen-
dent effects on the microbiota (Ryan et al., 2014). Thus, the find-
ings that elevatedbile acid levels in humans and/ormice areasso-
ciatedwithgastrointestinal diseases, hepatoxicity, alteredplasma
lipoprotein levels, and aberrant glucose metabolism suggest that
abnormal control of the bile acid pool can have broad physiolog-
ical effects (de Aguiar Vallim et al., 2013a; Kuipers et al., 2014).
Although negative feedback of bile acid synthesis was first
described over 50 years ago (Beher et al., 1961), the precise
mechanisms by which bile acids mediate this repression are still
not fully understood. The enzymatic catabolism of cholesterol, or
hydroxysterols, to form primary bile acids occurs via either the
classic or alternative pathways (Figure 1A). These two pathways
generate approximately 75% and 25%, respectively, of the total
primary bile acids and involve at least 17 enzymes (Russell, 2003)
(Figure 1A). Within the classic pathway, CYP7A1 is the rate-
limiting enzyme, while CYP8B1 regulates the synthesis of cholic
acid (Li-Hawkins et al., 2002) and thus regulates the bile acid
pool composition (Figure 1A). The transcription of both Cyp7a1
andCyp8b1 are particularly responsive to end product feedback
control (Russell, 2003). In contrast, the alternative bile acid
pathway involves CYP7B1 and CYP27A1 (Figure 1A) (Russell,
2003). Little is known about the regulation of the genes that
encode enzymes of the alternative pathway, or downstream of
CYP7A1 and CYP8B1. Nonetheless, the finding that a number
of diseases result from mutations of CYP7A1, CYP7B1,
CYP27A1, HSD3B7, AMACR, or AKR1C4 (Akr1c14 in mice) (Fig-
ure 1A) emphasizes the importance of maintaining normal bile
acid synthesis and homeostasis.
In humans and mice, one of the most abundant bile acids is
cholic acid (CA). Humans also have high levels of chenodeox-
ycholic acid (CDCA). In contrast, mice almost quantitativelyc.
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Figure 1. FXR Activation Represses Most Bile Acid Synthesis Genes
(A) Schematic diagram of the major hepatic enzymes involved in bile acid synthesis. Genes in red are repressed, while genes in yellow are unchanged, and the
gene in green is induced following FXR activation.
(B–D) Hepatic expression of genes encoding enzymes of the (B) classic or (C) alternative bile acid synthetic pathway or (D) remaining genes involved in primary
bile acid synthesis. mRNA levels were measured by qRT-PCR following treatment of wild-type or Fxr/ mice (7–9 mice/group) for 3 days with GW4064 or
GSK2324 at 60 mpk/day. All data are shown as mean ± SEM. Asterisks indicate statistically significant differences comparing WT or KO vehicle-treated against
agonist-treated mice (*p < 0.05; **p < 0.01; ***p < 0.001).convert CDCA to muricholic acid (MCA) (Figure 1A) (de Aguiar
Vallim et al., 2013a; Russell, 2003). The negative feedback
regulation of bile acid synthesis is largely dependent on activa-
tion of hepatic and/or intestinal FXR (Kim et al., 2007). Such
activation results in the induction of small heterodimerizing
partner (Shp, Nr0b2) in the liver (Kerr et al., 2002; Wang
et al., 2002) and Fgf15 (mouse) or FGF19 (human) in the small
intestine (Inagaki et al., 2005, 2006). SHP does not bind DNA
directly, but rather binds to other transcription factors such
as HNF4a and LRH-1 to impair their function (Ba˚vner et al.,
2005; Goodwin et al., 2000; Lu et al., 2000). In contrast, intes-
tinally derived FGF15/19 is secreted into the blood before
binding to the FGFR4/b-Klotho receptor on the surface of he-
patocytes to initiate an incompletely understood pathway that
leads to repression of Cyp7a1 (Inagaki et al., 2005). In contrast
to the detailed studies detailing the mechanisms that con-
trol Cyp7a1, the mechanisms involved in the repression of
Cyp8b1, and thus cholic acid synthesis, are less well under-
stood. Nonetheless, FXR activation is known to repress
Cyp8b1 expression by mechanisms that may also involveCell MSHP and FGF15/19 (Kerr et al., 2002; Kong et al., 2012;
Wang et al., 2002).
Here, we identify a previously unrecognized FXR-regulated
pathway involving MAFG (V-Maf Avian Musculoaponeurotic
Fibrosarcoma Oncogene Homolog G), a member of the MAF
family of transcription factors. We show that MafG is a direct
target gene of FXR, and hepatic overexpression of MAFG in
mice represses genes encoding enzymes of the classic and
alternative pathways. In addition, overexpression of MAFG in
mice resulted in a decrease in biliary cholic acid levels and an in-
crease in muricholic acid levels, a finding consistent with the
greater inhibition of Cyp8b1 as compared to Cyp7a1. Finally,
we utilize loss-of-function approaches (knockdown of MafG
with antisense oligonucleotides, MafG+/ mice) to show that a
50%–80% loss of hepatic MAFG protein results in both de-
repression of many of the same genes, including Cyp8b1, and
an increase in biliary cholic acid levels. In conclusion, our results
identify an FXR-MafG pathway that functions in the feedback
repression of bile acid metabolism by modulating the composi-
tion of the bile acid pool.etabolism 21, 298–310, February 3, 2015 ª2015 Elsevier Inc. 299
RESULTS
FXR Activation Represses Both the Classic and
Alternative Bile Acid Synthetic Pathways
Multiple studies have shown that activated FXR leads to
repressed transcription of both Cyp7a1 and Cyp8b1 (Kerr
et al., 2002; Kong et al., 2012; Wang et al., 2002). While the
mechanisms regulating Cyp7a1 expression have been exten-
sively studied, much less is known about how FXR represses
Cyp8b1 or whether FXR regulates the expression of other genes
involved in the two bile acid synthetic pathways. In our initial
studies, we treated wild-type and Fxr/ mice (KO) for 3 days
with either GW4064, a widely used FXR agonist (Maloney
et al., 2000), or GSK2324, a water-soluble derivative of
GW4064 that exhibits increased potency (Bass et al., 2011). As
expected, both agonists led to robust repression of both
Cyp7a1 andCyp8b1 in wild-type, but not Fxr/mice (Figure 1B).
Importantly, both agonists also resulted in an FXR-dependent
repression of Cyp7b1 and Cyp27a1 in the alternative pathway
(Figure 1C). In addition, we measured the hepatic mRNA levels
of a number of additional genes that encoded enzymes involved
in bile acid synthesis. We now show for the first time that FXR
activation in wild-type, but not Fxr/mice, results in repression
of numerous bile acid synthetic genes, including Acox2,
Akr1c14, Hsd3b7, Hsd17b4, Scp2, and Slc27a5 (Figure 1D). In
contrast, Amacr and Cyp39a1mRNA levels are unchanged (Fig-
ure 1D), while Akr1d1 is modestly induced after FXR activation,
consistent with ChIP-seq data that identify a putative intronic
FXRE in the Akr1d1 locus (Figure S1A). Overall, the repression
of most bile acid synthetic genes was not as pronounced as
that observed forCyp8b1 andCyp7a1 (Figure 1B). Nevertheless,
these studies demonstrate that treatment of mice with two
different synthetic FXR agonists results in repression of genes
involved in both the classic and alternative bile acid synthetic
pathways, consistent with a central role for FXR in regulating
all aspects of bile acid synthesis.
FXR Activation Induces the Expression of Several
Transcriptional Repressors
The nuclear receptor FXR binds to its cognate response element
(FXRE) as an FXR:RXR heterodimer and functions almost exclu-
sively as a transcriptional activator (de Aguiar Vallim et al.,
2013a). Nonetheless, although activation of FXR leads to induc-
tion of many hepatic genes, it also results in repression of
numerous genes involved in bile acid metabolism (Figure 1D).
A number of studies have demonstrated that the mechanisms
involved in the repression of Cyp7a1 and Cyp8b1 are indirect
and are the result of the FXR-dependent increased expression
of Shp and Fgf15/19 that encode proteins that function to inhibit
transcription of specific genes (de Aguiar Vallim et al., 2013a;
Kuipers et al., 2014). One additional mechanism by which FXR
causes a reduction in specific genes is through miRNAs. For
example, we recently identified miR-144 as an FXR-regulated
miRNA that subsequently targets ABCA1 (de Aguiar Vallim
et al., 2013b). Based on these earlier studies, we hypothesized
that FXR activation might increase the expression of additional
repressors that function to control metabolic pathways.
To identify such putative transcriptional repressors, we re-
analyzed the data from our prior ChIP-seq study that had been300 Cell Metabolism 21, 298–310, February 3, 2015 ª2015 Elsevier Inused to identify global hepatic FXR response elements (FXREs)
(Chong et al., 2010). Gene ontology analysis identified a signifi-
cant enrichment in transcription factors containing FXREs
(Chong et al., 2010). Consequently, we searched this subset of
FXRE-containing genes, focusing specifically on genes anno-
tated to have transcriptional repressor activity. Our analysis
identified four putative transcriptional repressor genes, namely
Shp, a well-characterized FXR target gene, v-maf musculoapo-
neurotic fibrosarcoma oncogene homolog G (avian) (MafG),
cysteine-rich intestinal protein 2 (Crip2), and zinc finger protein
385a (Zfp385a). We also identified a fifth putative transcriptional
repressor, oligodendrocyte transcription factor 1 (Olig1), which
we show can be regulated by FXR agonists (Figure S1B) and
contains an FXRE in its genomic loci. However, since the hepatic
expression of Olig1 is very low (data not shown), we have not
studied this gene further.
To confirm the presence of FXREs at the loci of these putative
transcriptional repressors, we analyzed a second independent
FXR ChIP-seq dataset from mouse livers (Thomas et al., 2010).
This analysis verified that Crip2 (Figure 2A), MafG (Figure 2B),
Zfp385a (Figure 2C), and Shp (Figure S1C) contained one or
more FXREs at their genomic loci. To investigate whether these
genes were regulated in response to FXR and FXR agonists, we
measured the hepatic expression ofCrip2,MafG, and Zfp385a in
wild-type and Fxr/mice (KO) pre-treated for 3 days with either
GW4064 or GSK2324. We utilized a dose of 60 mpk/day to
directly compare the effects of the two agonists. In all experi-
ments, Shp and/or Bsep, both well-characterized FXR-target
genes (Ananthanarayanan et al., 2001; Goodwin et al., 2000),
served as positive controls. Hepatic MafG, Crip2, Zfp385a, and
Shp mRNA levels were all significantly induced following treat-
ment of wild-type mice, but not Fxr/ mice (KO), with either
FXR agonist (Figure 2D), demonstrating that induction was FXR
dependent. Further, induction of each gene was greater after
treatment with GSK2324 as compared to GW4064 (Figure 2D),
consistent with increased potency of GSK2324. In the case of
MAFG, the levels of protein were induced 2- to 3-fold following
treatment of mice with either GW4064 or GSK2324, and this ef-
fect was specific, as it was not observed in Fxr/ mice treated
with either agonist (Figure 2E).
In order to determine whether cholic acid, an endogenous
ligand that activates a number of receptors, including FXR
(Makishima et al., 1999; Parks et al., 1999), induces these
same genes, we fed wild-type and Fxr/ mice (KO) a diet con-
taining non-toxic levels of cholic acid (0.2%) for 7 days. The
hepatic expression of MafG and Zfp385a (Figure 2F), as well as
the positive controls Bsep (Figure 2F) and Shp (Figure S1D),
were modestly induced when wild-type, but not Fxr/ mice,
were fed the cholic acid-enriched diet. In contrast, the increase
in Crip2 mRNA levels did not reach statistical significance (Fig-
ure 2F). Taken together, these results demonstrate that MafG,
Crip2, and Zfp385a, which encode putative transcriptional re-
pressors, are induced by specific FXR agonists (GSK2324 and
GW4064), while MafG and Zfp385a are also induced by cholic
acid, an endogenous FXR ligand.
To determine the optimal dose of GSK2324, we treated
wild-type mice for 3 days with vehicle or 10, 30, or 100 mpk
GSK2324. Induction of the classic FXR target genes Shp
and Bsep was dependent upon the dose of GSK2324 withc.
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Figure 2. Identification of Transcriptional Repressors as Direct FXR Target Genes
(A–C) ChIP-seq analysis of hepatic FXR from Chong et al. (2010) (top) and Thomas et al. (2010) (bottom) at (A) Crip2, (B) MafG, and (C) Zfp385a genomic loci.
(D) Hepatic expression of Shp,MafG, Crip2, and Zfp385a in C57BL/6 wild-type (WT) and Fxr/ (KO) mice treated with vehicle, GW4064, or GSK2324 for 3 days
(n = 7–9 mice/group).
(E) Western blotting analysis and quantification of MAFG protein in livers of C57BL/6 wild-type and Fxr/mice treated with vehicle or GW4064 (top), or GSK2324
(bottom) for 3 days.
(F) Hepatic expression of Bsep,Crip2,MafG, and Zfp385a in C57BL/6 wild-type and Fxr/mice fed either a control (Ctr) or 0.2% cholic acid (CA) diet for 7 days.
(G) Hepatic expression ofCrip2,MafG, and Zfp385a in C57BL/6 wild-typemice treated with vehicle (Ctr) or 10, 30, or 100mpk/day of GSK2324 for 3 days (n = 4–8
mice/group).
(H) Hepatic expression ofCrip2,MafG, and Zfp385a following treatment of wild-type mice with a single injection of GSK2324 (30mpk) 1, 2, or 4 hr before sacrifice
(n = 6 mice/group).
(I) Hepatic expression of Crip2, MafG, and Zfp385a in littermate C57BL/6 wild-type (Flox) or liver-specific Fxr/ mice (L-KO) treated with GSK2324 for 3 days
(n = 7–9 mice/group). All data are shown as mean ± SEM. Asterisks indicate statistically significant differences comparing WT or KO vehicle-treated against
agonist-treated mice (**p < 0.01; ***p < 0.001).
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near-maximal effects at 30 mpk (Figure S2A). Induction of Crip2,
MafG, and Zfp385a was also dependent upon the dose of
GSK2324 (Figure 2G). Further, a single dose of GSK2324 at 30
mpk resulted in a significant induction of Crip2, MafG, and
Zfp385a (Figure 2H) andShp andBsep (Figure S2B)mRNA levels
within 1 hr. To investigate whether induction of Crip2,MafG, and
Zfp385a in response to GSK2324 is dependent upon hepatic
FXR expression, we treated wild-type (Fxrflox/flox) mice or litter-
mates lacking hepatic Fxr (FxrL/L; L-KO) for 3 days with the
agonist at 30 mpk. While GSK2324 treatment of Fxrflox/flox mice
led to increased hepatic expression of Crip2, MafG, Zfp385a,
and Shp, induction of these genes was not observed following
GSK2324 treatment of FxrL/L mice (Figure 2I; Figure S2C).
Taken together, our results demonstrate that Crip2, MafG, and
Zfp385a are acutely and robustly induced following activation
of hepatic FXR.
MafG Overexpression In Vivo Decreases Cyp8b1 and
Biliary Cholic Acid Levels
To investigate the potential repressive effects of MafG, Crip2,
and Zfp385a on gene expression, we generated, and then in-
jected, adenoviral vectors to acutely overexpress these three
proteins in the livers of wild-type mice. We then measured the
hepatic mRNAs of the two major bile acid synthetic enzymes,
as these are robustly repressed following activation of FXR (Fig-
ure 1B). Ad-MafG, but not Ad-Crip2 or Ad-Zfp385a treatment, re-
sulted in a decrease in the hepatic levels of Cyp8b1 (Figure 3A).
In contrast, the expression of Cyp7a1 was unaffected by any of
these treatments (Figure 3A).
The MafG-dependent repression of Cyp8b1 suggests that
MAFG may regulate the synthesis of cholic acid and alter the
bile acid pool composition. To determine whether MAFG overex-
pression could indeed change the biliary pool composition,
we treated a new cohort of mice with either Ad-control or Ad-
MafG adenovirus. Changes in the composition of the bile acid
pool are relatively slow under normal conditions, since only 5%
of the bile acids are excreted each day during multiple enterohe-
patic cycles (de Aguiar Vallim et al., 2013a; Hofmann and Hagey,
2008). Consequently, we fed mice either control diet (chow) or
the same diet supplemented with a bile acid sequestrant
(0.25% Colesevelam/Welchol) for 7 days prior to treatment
with Ad-control or Ad-MafG. Bile acid sequestrants bind bile
acids in the intestine, preventing their re-absorption in the ileum
and promoting bile acid excretion in the feces (Hofmann and Ha-
gey, 2008). The result is impaired enterohepatic re-circulation of
bile acids, de-repression of genes involved in bile acid synthesis,
and changes in the bile acid pool size (Hofmann and Hagey,
2008; Kong et al., 2012). As expected, Ad-MafG increased the
hepatic expression of MAFG mRNA (Figure 3B) and protein (Fig-
ure 3C and full blot in Figure S2D), regardless of the presence
or absence of the bile acid sequestrant in the diet. The bile
acid sequestrant-containing diet increased basal expression of
Cyp8b1, as expected (Figure 3D). Importantly, Ad-MafG treat-
ment of both the control and Colesevelam-fed mice resulted in
a significant repression ofCyp8b1mRNA (Figure 3D). Consistent
with this decrease inCyp8b1mRNA,we observed a concomitant
decrease in cholic acid and an increase in muricholic acid levels
in the bile of Ad-MafG-treated mice (Figure 3E). Moreover, the
MafG-dependent changes in bile acids were qualitative, not302 Cell Metabolism 21, 298–310, February 3, 2015 ª2015 Elsevier Inquantitative, as total bile acid levels in the liver, intestine, or
gall bladder (Figures S2E–S2G) were similar in mice treated
with Ad-control, Ad-MafG, Ad-Crip2, or Ad-Zfp385a. Thus, these
two studies demonstrate that the MafG-dependent repression
of Cyp8b1 is sufficient to decrease cholic acid and increase
muricholic acid levels, even after acute (7 days) and modest in-
creases (2- to 3-fold) in MAFG protein.
To determine whether the pathway described here is
conserved in human cells, we treated the human hepatoma
cell line HepG2 with increasing concentrations of CDCA, a
natural FXR agonist (Makishima et al., 1999; Parks et al., 1999).
Consistent with our observations in mouse liver, CDCA
treatment increased the expression of both MAFG (Figure 3F)
and SHP (Figure S2H). As expected, CDCA treatment also
decreased CYP7A1 and CYP8B1 expression in a dose-depen-
dent manner (Figure 3G). Finally, Ad-MafG, but not Ad-Crip2
or Ad-Zfp385a, treatment of HepG2 cells decreased CYP8B1
expression without affecting CYP7A1 (Figure 3H). Thus, we
have identified a pathway whereby MAFG represses CYP8B1
expression both in mice and in human cells.
To further characterize the FXR-dependent regulation of
MafG, we carried out more in-depth analysis. The MafG gene
is reported to contain two transcriptional start sites that corre-
spond to exon 1a or exon 1b (Katsuoka et al., 2005a) (Figure 3I).
However, our analysis of hepatic RNA-seq data fromMenet et al.
(2012) (Figure 3I, upper panel) together with the data of Katsuoka
et al. (2005a) suggest that in the liver, MafG is preferentially
transcribed from exon 1b (Figure 3I). Thus, the putative FXRE
identified by ChIP-seq analysis (Figure 2B) would reside in the
hepatic MafG proximal promoter that lies upstream of exon 1b
(Figure 3I). Consequently, we generated a luciferase reporter
gene controlled by the hepatic MafG promoter (upstream of
exon 1b). Treatment of cells with GSK2324, following co-trans-
fection of plasmids expressing FXR and the reporter gene, led
to a robust increase in luciferase activity (Figure 3J). In contrast,
the FXR- and GSK2324-dependent increase in luciferase activity
was abolishedwhen the FXRE, which corresponds to an inverted
repeat 1 (IR-1), was mutated in the MafG promoter construct
(Figure 3J). Taken together, these data demonstrate that MafG
is a bona fide FXR target gene that contains a functional FXRE
in its hepatic proximal promoter.
MAFG Overexpression in Mouse Liver Represses
Numerous Genes Involved in Bile Acid Metabolism
MAFG is a member of the small MAF family of transcription
factors, composed of MAFG, MAFF, and MAFK, that lack an
activation domain and therefore are considered transcriptional
repressors (Motohashi et al., 2002). Small MAF proteins can
bind to DNA as either homo- or hetero-dimers and function as
transcriptional repressors. Alternatively, they can heterodimerize
with transcriptional activators to induce gene expression (Moto-
hashi et al., 2002). Consistent with their role as transcription
factors, we show that epitope-tagged MAFG localizes to the
nucleus (Figure S3A). MafG is expressed in several metabolic
tissues, including the liver (Figure S3B), the major site for bile
acid synthesis.
To determine if MAFG overexpression regulated additional
genes of bile acid metabolism, in addition to Cyp8b1, we carried
out gene expression profiling of livers of mice treated with eitherc.
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Figure 3. MafG Overexpression Represses Cyp8b1 mRNA and Reduces Biliary Cholic Acid Levels
(A) Hepatic expression of Cyp7a1 and Cyp8b1 following treatment of C57BL/6 mice with Ad-control (Ad-Ctr), Ad-Crip2, Ad-MafG, or Ad-Zfp385a adenoviruses
for 5 days (n = 7–8 mice/group).
(B–E) Hepatic levels of (B)MafGmRNA, (C) MAFG protein, and (D) Cyp8b1mRNA and (E) taurine-conjugated biliary bile acid levels in C57BL/6 wild-type treated
with Ad-control or Ad-MafG adenovirus for 7 days and fed either a control or Colesevelam-containing diet (Colesev) for 7 days prior to and 7 days post-adenovirus
treatment (n = 8–9 mice/group).
(F and G) Expression levels of (F)MAFG or (G) CYP7A1 and CYP8B1 in human HepG2 cells treated with 100, 150, or 200 mM chenodeoxycholic acid (CDCA) for
24 hr (n = 4 wells/condition).
(H) Expression levels of CYP7A1 and CYP8B1 in HepG2 cells infected with Ad-Control, -Crip2, -MafG, or -Zfp385a for 36 hr (n = 3–4 wells/condition).
(I) RNA-seq (Menet et al., 2012) (top) and FxrChIP-seq (Chong et al., 2010) (bottom) analysis of theMafG genomic loci showing locations of MafG exons and FXRE
in the putative MafG proximal promoter.
(J) Wild-type and FXRE mutant (mutated bases are bolded and underlined) MafG promoter (MafG prom) constructs upstream of a luciferase reporter gene were
transfected into HepG2 cells with increasing amounts of a FXR expression plasmid and treated with vehicle or GSK2324 for 24 hr. Luciferase activity was
normalized to b-galactosidase and expressed as fold change. All data are shown as mean ± SEM. Asterisks indicate statistically significant differences versus
controls (**p < 0.01; ***p < 0.001). Different letters (a–d) indicate statistically significant differences (p < 0.05).
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Figure 4. MAFG Regulates Several Genes Involved in Bile Acid Synthesis
(A) Microarray analysis of livers from mice treated with either Ad-control or Ad-MafG for 7 days. Lines delineate fold-change cut-off (1.5-fold). Red and blue dots
indicate genes that are repressed or induced genes, respectively (n = 3/condition).
(B) KEGG pathway analysis for categories that were significantly enriched from global analysis of repressed genes in (A).
(C) Hepatic expression of genes involved in bile acid synthesis or transport following treatment of C57BL/6 wild-type with Ad-control or Ad-MafG adenovirus for
7 days and fed either a control or Colesevelam-containing diet for 7 days prior to and 7 days post-adenovirus treatment (n = 8–9 mice/group). All data are shown
as mean ± SEM. Asterisks indicate statistically significant differences versus controls on the same diet (**p < 0.01; ***p < 0.001).control or MafG adenovirus (Figure 4A). MAFG overexpression
repressed 554 genes and activated 833 genes. Induction of
genes in response to MAFG overexpression is not unexpected,
as MAFG can heterodimerize with transcriptional activators,
most notably NRF2 and NRF3, to activate specific genes (Kat-
suoka et al., 2005a, 2005b). Gene ontology analysis (Huang
et al., 2009) of the hepatic genes that are repressed following
MAFG overexpression revealed a significant enrichment in pri-
mary bile acid synthesis genes (Figure 4B) that included
Cyp8b1 and Cyp7b1, as well as the bile acid importer, sodium
taurocholate co-transporting polypeptide (Ntcp, gene symbol
Slc10a1). Interestingly, these same genes are also repressed in
mouse liver following treatment with FXR agonists (Figures 1B–
1D), suggesting that the repression of these genes by FXR ago-
nists is indirect and likely dependent upon induction of MAFG
mRNA and protein levels.
We also determined the expression of the remaining bile acid
synthesis genes in Ad-control and Ad-MafG-treated mice that
had been fed either normal chow or a diet supplemented with
0.25% Colesevelam. Ad-MafG treatment resulted in repression
of almost all bile acid synthesis genes, including Cyp7b1 and304 Cell Metabolism 21, 298–310, February 3, 2015 ª2015 Elsevier InCyp27a1, independent of the diet (Figure 4C). Interestingly, com-
parison of the data shown in Figures 4C and 1D demonstrates
that the bile acid synthetic genes that are repressed following
FXR activation are also repressed following overexpression of
MAFG. The repression of bile acid synthesis genes is not univer-
sal, since Amacr and Cyp39a1 mRNA levels were unchanged
following treatment ofmicewith FXR agonists or following hepat-
ic overexpression of MAFG (Figures 1D and 4C). Together, these
data suggest that MAFG is an important transcriptional regulator
of bile acid synthesis andmay play an important role inmediating
the FXR-dependent repression of genes involved in bile acid
metabolism.
Loss of MAFG Causes De-Repression of Multiple Bile
Acid Synthetic Genes and Increases Biliary Cholic Acid
Levels
To further evaluate the role ofMafG in regulating bile acid meta-
bolism, we investigated the effect of loss of MafG. Short-term
silencing of MafG in isolated mouse hepatocytes using three
distinct shRNA constructs (Figure 5A) resulted in de-repression
of Cyp8b1 (Figure 5B). Further, siRNA-mediated silencing ofc.
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Figure 5. Loss of MafG Results in De-Repression of Several Bile Acid Synthetic Genes
(A and B) Expression of (A)MafG and (B) Cyp8b1 in primary mouse hepatocytes treated with control (Ad-sh-LacZ) or three differentMafG shRNA adenoviruses
(Ad-sh-MafG 1–3) (n = 4 wells/condition).
(C and D) Shown are (C)MAFGmRNA and protein (inset; bA, b-actin) and (D)CYP8B1 expression in HepG2 cells treated with control orMAFG siRNA (n = 3 wells/
condition).
(E) Hepatic MafG mRNA in C57BL/6 wild-type mice treated with control or MafG ASO (100 mpk) for 3 days (n = 9 mice/group).
(F) Hepatic MafG protein from mice treated as in (E).
(G) Hepatic Cyp7a1 and Cyp8b1 mRNA from mice treated as in (E).
(H and I) Shown are (H)MafGmRNA and protein (top) and (I)Cyp7a1,Cyp8b1,Cyp27a1, and Cyp7b1mRNA levels in littermate wild-type andMafG+/ (Het) mice
(n = 7–11 mice/group).
(J) Biliary bile acid levels were determined from individual littermate wild-type and MafG+/ mice (n = 7–11/group).
(K) Hepatic expression of bile acid synthesis genes in littermate wild-type andMafG+/mice (n = 7–11mice/group). All data are shown as mean ± SEM. Asterisks
indicate statistically significant differences versus controls or wild-type (*p < 0.05; **p < 0.01; ***p < 0.001).MAFG mRNA and protein levels in human HepG2 cells (Fig-
ure 5C) also led to de-repression of CYP8B1 (Figure 5D).
Together, these results suggest that MafG is a critical negative
regulator of Cyp8b1 expression in both mice and humans. We
then generated an antisense oligonucleotide (ASO) to silence
MafG in vivo. Acute treatment with the MafG ASO significantly
decreased the levels ofMafGmRNA (Figure 5E) and protein (Fig-
ure 5F, full blot in Figure S4A). Notably,Cyp8b1, but not Cyp7a1,
was de-repressed in mice after MafG silencing with the ASO
treatment (Figure 5G), thus recapitulating our in vitro findings in
an in vivo setting.
To determine whether complete loss ofMafG also affected bile
acidhomeostasis,weobtainedMafG+/mice,whichare reported
to generate viableMafG/mice on a mixed background (Shavit
et al., 1998).We then backcrossedMafG+/mice onto aC57BL/6
background for 10 generations to be consistent with the genetic
background of all other mice used in the current studies. Unex-
pectedly, we failed to recover any MafG/ mice on a C57BL/6
background (data not shown). We conclude that complete loss
ofMafG on a C57BL/6 background is lethal, likely a result of pro-
nounced neurological disorders previously reported in MafG/
mice on amixed genetic background (Shavit et al., 1998). Conse-
quently, our studies are limited to heterozygous MafG+/ mice
and their wild-type littermates. As expected, hepatic MafG
mRNA and protein levels are decreased approximately 50%Cell Min MafG+/ mice (Figure 5H). Importantly, Cyp8b1, but not
Cyp7a1, mRNA levelswere induced/de-repressed in theMafG+/
mouse liver (Figure 5I). Other genes, such as Cyp7b1 and
Cyp27a1, thatwehaveshownare repressed followingMafGover-
expression (Figure 4C) were also de-repressed in the livers of
chow-fed MafG+/ mice (Figure 5I). Importantly, partial loss of
MafGmRNA and protein led to a significant increase in the biliary
levels of cholic acid and decreased muricholic acid levels in
MafG+/ mice (Figure 5J), consistent with de-repression of
Cyp8b1. MafG+/ mice do not have significantly altered total
bile acid levels in liver, intestine, or gall bladder (Figures S4B–
S4D), suggesting that MAFG regulates the bile acid pool compo-
sition, but not the pool size. We quantified the expression of
multiple genes encoding enzymes of the bile acid synthetic
pathway in the livers of wild-type andMafG+/ mice. Partial loss
of MAFG caused de-repression of several genes, including
Acox2, Akr1d1, Akr1c14, Hsd17b4, Ntcp, and Scp2 (Figure 5K).
Collectively, these results support the hypothesis that hepatic
MAFG functions asa repressor ofCyp8b1andcholic acid synthe-
sis as well as a regulator of bile acid metabolism in vivo.
Identification of MAFG Binding Sites at Multiple Genes
Involved in Bile Acid Synthesis and Metabolism
To investigate the molecular mechanism for the MafG-depen-
dent repression of Cyp8b1 as well as additional target genes,etabolism 21, 298–310, February 3, 2015 ª2015 Elsevier Inc. 305
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Figure 6. Identification of MAREs in Bile Acid Synthetic Genes
(A) Hepatic levels of MAFG protein levels (detected using anti-BLRP or anti-MAFG antibodies) in C57BL/6 mice treated with either control (Ad-BLRP) or BLRP-
tagged MAFG adenovirus (Ad-BLRP-MafG).
(B) Global frequency of hepatic MAFG binding sites (MAREs) across the genome relative to gene location (expressed as a percentage).
(C) Table showing the motif for the top 20,000 peaks in MAFG ChIP-seq peaks (top) and in all 68,754 peaks (bottom), with statistical significance and percent
occurrence in peaks (target) or background (bkgd).
(D) ChIP-seq analysis of MAREs in chromatin isolated from livers of mice treated with Ad-BLRP (control; top) or Ad-BLRP-MafG (bottom) at Cyp8b1 locus.
(E) ChIP analysis of MafG occupancy at the Cyp8b1 promoter region determined by qRT-PCR (primer locations to scale, y axis).
(F) Wild-type and MARE Cyp8b1 promoter luciferase constructs were transfected into HepG2 cells and co-transfected with increasing amounts of a MAFG
expression plasmid. Luciferase activity was normalized to b-galactosidase and expressed as fold change.
(G and H) ChIP-seq analysis of MAREs in chromatin isolated from livers of mice treated with Ad-BLRP (control; top) or Ad-BLRP-MafG (bottom) at loci for (G)
Cyp27a1 or (H) Cyp7b1.
(I) Cyp7b1 promoter-luciferase reporter transfected into HepG2 cells together with increasing amounts of a MAFG expression plasmid. Luciferase activity was
normalized to b-galactosidase and expressed as fold change. All data are shown as mean ± SEM. Asterisks indicate statistically significant differences from
control (**p < 0.01; ***p < 0.001).we generated an adenovirus construct to overexpress a biotin-
ligase recognition peptide (BLRP)-tagged MafG. Consistent
with our studies using untagged MAFG (Ad-MafG) (Figures 3A–
3D), treatment ofmicewith Ad-BLRP-MafG resulted in increased
hepatic MafG mRNA (Figure S5A) and protein (Figure 6A) and
decreased Cyp8b1, Cyp7b1, and Cyp27a1 expression (Fig-
ure S5B), suggesting the BLRP epitope does not interfere with
MAFG function. We then used ChIP analysis to identify MAFG
bound to MAFG response elements (MAREs). First, as controls
we show that in mouse liver, BLRP-tagged MAFG was enriched
at MAREs that had been previously identified in Nqo and G6pdx
in studies using cultured cells (Hirotsu et al., 2012) (Figure S5C).
We then carried out ChIP-seq analysis from livers of mice treated306 Cell Metabolism 21, 298–310, February 3, 2015 ª2015 Elsevier Inwith Ad-BLRP-MafG as well as Ad-BLRP (control), using the
same anti-BLRP antibody. Global analysis of all peaks for
MAFG revealed that 46% reside in intergenic regions, as
compared to 41% in introns, while there was a modest enrich-
ment in proximal promoters (Figure 6B). Motif enrichment anal-
ysis of sequences for the top 20,000 MAFG peaks (representing
the largest number of reads per site) identified the consensus
MARE (Figure 6C, top). This sequence is highly similar to the
MARE described previously for MAFG homodimers (Hirotsu
et al., 2012). Analysis of all MAFG ChIP-seq peaks (n = 68,754)
identified a MARE that contained a consensus sequence of
GTCAGC (Figure 6C, bottom) but was otherwise different from
that found in the top 20,000 peaks. Presumably, the latterc.
Figure 7. Summary for the Role of MAFG in Regulating Bile Acid
Synthesis and Transport
The cartoon shows the activation of theMafG gene following FXR activation by
various ligands (yellow boxes) and the subsequent targeting of MAFG protein
(purple) to several MAREs. MAREs identified in the current study that lie within
the genomic loci of MAFG-repressed genes (shown in red) that encode pro-
teins involved in bile acid synthesis or metabolism are identified. Below is a
simplified version of the classic and alternative bile acid synthetic pathways
that generate cholic acid (CA), chenodeoxycholic acid (CDCA), or muricholic
acid (MCA).MARE represents various binding sites for complexes containing
different MAFG-containing heterodimers. The MARE motif iden-
tified in the top MAFG 20,000 peaks was present in 59% of all
peaks, whereas the same motif was present in 4% of the Ad-
BLRP-control (Figure 6C). Similarly, analysis for all 68,754 peaks
identified the differentMAREmotif in 42%of peaks, compared to
4% in the background control (Figure 6C).
We next searched the Cyp8b1 locus of the MAFG ChIP-seq
data. This identified a number of MAREs within 10 kb of the
Cyp8b1 gene (Figure 6D, lower panel) and one peak present
near the transcriptional start site (TSS). We confirmed the enrich-
ment of MAFG in the Cyp8b1 proximal promoter by qRT-PCR
ChIP analysis (Figure 6E). Complementary analysis of the
Cyp8b1 promoter (0.5 kb) using luciferase reporter assays
demonstrated a dose-dependent repression following MAFG
overexpression (Figure 6F). In contrast, mutation of the MARE
within the Cyp8b1 promoter resulted in de-repression of the
luciferase reporter gene, which was no longer repressed by
MAFG overexpression (Figure 6F). These results demonstrate
direct binding of MAFG to multiple sites upstream of Cyp8b1,
and to one site in the proximal promoter, that identify the molec-
ular mechanism for the MAFG-dependent repression ofCyp8b1.
MAFG ChIP-seq analysis also identified MAREs in the pro-
moter and/or intronic regions of Cyp27a1 (Figure 6G, lower
panel) and Cyp7b1 (Figure 6H, lower panel). In contrast, peaks
for MAFG binding sites were not present in ChIP-seq data from
mice treated with the control Ad-BLRP (Figures 6D, 6G, and
6H, upper panels). Analysis of the proximalCyp7b1 promoter us-
ing a luciferase reporter gene showed that MAFG overexpres-
sion reduced luciferase activity in a dose-dependent manner
(Figure 6I). Further, we also identified MAREs in several otherCell Mbile acid synthetic genes, including Acox2, Akr1d1, Akr1c14,
Ntcp, Hsd17b4, and Scp2 (Figures S5D–S5I), but not in the
100 kb upstream of Cyp7a1 (Figure S5J). Together, these data
demonstrate that MAFG directly regulates several bile acid
metabolism genes.
Interestingly, liver-specific LRH-1-deficient mice also have
decreased Cyp8b1, unchanged Cyp7a1, and altered bile acid
composition (Lee et al., 2008; Mataki et al., 2007). We therefore
investigated whether MAFG binding sites were associated with
LRH-1 occupancy in the liver. UsingChIP-seq analysis for hepat-
ic LRH-1 sites (Chong et al., 2012), we only identified a small
number of genes that had both MAFG and LRH-1 binding sites
(282 of 10,351; Figure S6A), and these genes were enriched in
genes of negative regulation of metabolic processes, but not
bile acid synthesis genes (Figure S6B). Taken together, these
results suggest that MAFG is unlikely to repress transcription
of multiple bile acid synthetic genes by displacing LRH-1.
In conclusion, our extensive studies identify a pathway
involving the nuclear receptor FXR and the FXR-target gene
MafG that functions to repress transcription of Cyp8b1 as well
as multiple bile acid genes, including Acox2, Akr1d1, Akr1c14,
Cyp7b1, Cyp27a1, Hsd17c14, Ntcp, and Scp2, and thus modu-
late bile acid homeostasis (Figure 7).
DISCUSSION
The current studies identify an FXR-MAFG pathway that controls
the transcription of multiple genes involved in both the classic
and alternative pathways of bile acid synthesis, and bile acid
transport. We show that the MafG gene is a direct target
of FXR and that MAFG subsequently represses many genes
involved in bile acid synthesis and metabolism (Figures 1, 2, 3,
4, and 7). Further, we show that loss of R50% hepatic MAFG
leads to de-repression of many of these genes (Figure 5). Impor-
tantly, we demonstrate that MAFG binds to MAREs associated
with the same repressed genes (Figures 6 and 7). Cyp8b1 or
Cyp7b1 promoter-reporter assays provided additional insight
into the functional importance of selected MAREs (Figure 6).
The identification of a MAFG-dependent regulation of Cyp8b1,
Acox2, Akr1d1, Akr1c14, Cyp27a1, Cyp7b1, Hsd17c4, Ntcp,
and Scp2 suggests a concerted action of MAFG in regulating
various aspects of bile acid metabolism that has not been
previously appreciated (Figure 1A).
Consistent with the finding that hepatic overexpression of
MAFG inmice repressesCyp8b1, we show that under these con-
ditions there is a decrease in biliary cholic acid and an increase
in muricholic acid levels (Figure 3) without increasing bile acid
levels in liver, intestine, or gall bladder (Figures S2E–S2G). This
finding is consistent with Cyp8b1 encoding the regulatory
enzyme for cholic acid synthesis from 7-hydroxycholesterol
and the earlier observation that Cyp8b1/ mice not only fail to
synthesize cholic acid, but exhibit increased muricholic acid
levels in bile, without a change in the bile acid pool size (Li-Haw-
kins et al., 2002). In contrast, loss of MAFG, as a result of partial
gene ablation or silencing, caused de-repression ofCyp8b1 (Fig-
ure 5) and an increased ratio of cholic acid:muricholic acid
without altering total bile acid levels in liver, intestine, and gall
bladder (Figures S4B–S4D). This change in the bile acid compo-
sition is expected to alter the hydrophobicity. However, theetabolism 21, 298–310, February 3, 2015 ª2015 Elsevier Inc. 307
physiologic consequences of such a change onmetabolism as a
whole are unknown and will require additional studies.
We did not observe changes in Cyp7a1 mRNA levels in the
MafG+/mice or in ASO-treated wild-typemice (Figure 5), further
supporting the specificity of the regulation of specific bile acid
genes by MAFG. Nonetheless, after prolonged MAFG overex-
pression, we have observed some repression of Cyp7a1 (data
not shown). This effect was not consistent across all our studies.
Since MafG silencing and MafG+/ mice do not exhibit changes
in Cyp7a1 expression (Figure 5), and MAFG ChIP-seq analysis
at the Cyp7a1 locus did not identify MAFG binding sites (Fig-
ure S5J), we suggest that the repression of Cyp7a1 may be
indirect.
The current studies suggest that MAFG represents a compli-
mentary pathway that is critical for the regulation of bile acid ho-
meostasis. Previous studies reported that the FXR-dependent
regulation of Cyp8b1 involves Shp (Kerr et al., 2002; Wang
et al., 2002), although the authors suggested at that time that
additional unknown pathways were likely to play a role in the
repression of bile acid synthetic genes. Earlier in vitro studies
had shown that SHP can repress luciferase reporter gene activity
by binding to and inhibiting HNF4a and LRH-1 transcription
factors that normally activate Cyp7a1 and/or Cyp8b1 (Goodwin
et al., 2000; Lu et al., 2000). Nonetheless, the effects of hepatic
overexpression of SHP on the expression of Cyp7a1 or
Cyp8b1 in vivo are at best very modest (Kir et al., 2012; Kong
et al., 2012), while the effects of SHP overexpression on other
bile acid synthetic genes or bile acid composition have not
been reported. Further, Kong et al. (2012) reported that treat-
ment of Shp/ mice with the FXR agonist GW4064 resulted in
near-normal repression of both Cyp8b1 and Cyp7a1. Taken
together, these results contrast with the broad and significant
repression of numerous bile acid synthetic genes and the
decreased levels of cholic acid we observe in mice following
MAFG overexpression (Figures 3 and 5).
A second pathway that leads to repression ofCyp7a1 involves
activation of FXR in enterocytes and the resulting increase in
Fgf15 (mouse) or FGF19 (humans) and subsequent secretion of
the protein (Inagaki et al., 2005). FGF15/19 binds to the cognate
receptor, FGFR4/b-klotho, resulting in repression of Cyp7a1
(Potthoff et al., 2012). Whether the FGF15/19 pathway plays a
role in the regulation of Cyp8b1 is unclear at the present time.
A recent study also demonstrated a co-requirement for SHP in
mediating the effects of FGF19 repression of Cyp7a1 (Kir et al.,
2012). In contrast, a separate study showed that injection of
FGF15 protein into Shp/ mice resulted in near-normal repres-
sion of both Cyp7a1 and Cyp8b1 (Kong et al., 2012). Thus, it ap-
pears that the precise role of SHP in mediating the FGF15/19
and/or FXR-dependent repression of Cyp8b1 and/or Cyp7a1 re-
mains to be established. Nonetheless, the finding that Cyp7a1
and/or Cyp8b1 mRNA levels are induced/de-repressed in cells
or the livers of mice deficient for either Shp (Kerr et al., 2002;
Wang et al., 2002), Fgfr4/b-klotho (Kong et al., 2012), or MafG
(Figure 5) suggest that SHP, FGF15/19, and MAFG represent
three complimentary pathways that control bile acid synthesis
and composition. Indeed, the existence and complexity of the
complementary pathways highlight the fact that tight regulation
of bile acid homeostasis is required, and dysregulation can
lead to various metabolic diseases.308 Cell Metabolism 21, 298–310, February 3, 2015 ª2015 Elsevier InThe role of MAFG in bile acid metabolism has not been
previously appreciated. The MAF family of proteins is divided
into small (MAFG, MAFF, and MAFK) and large (cMAF, MAFA,
MAFB) members (Kannan et al., 2012). The small members
contain a DNA-binding domain and a basic leucine zipper but
lack the transcriptional activation domain found in the large
family members (Kannan et al., 2012; Motohashi et al., 2002).
Small members of the family can form homodimers or hetero-
dimers that bind MAREs to repress transcription of target genes
(Kurokawa et al., 2009). However, the small MAF proteins can
also dimerize with transcriptional activators, such as NRF2, a
member of the Cap ‘n’ Collar family of transcription factors, to
induce genes involved in the stress response and detoxification
(Kannan et al., 2012; Motohashi et al., 2002). At the current time,
the factors that control the formation of homodimers versus
heterodimers of the small MAF proteins are poorly understood.
Feedback repression of bile acid synthesis in response to
accumulating bile acids is critical for the normal maintenance
of bile acid homeostasis and for the prevention of hepato-toxicity
that occurs with elevated levels of bile acids. The identification of
the pathway described here may have important implications in
disease since bile acid metabolism is linked to several metabolic
disorders, including cardiovascular disorders, diabetes, and
specific types of cancer.EXPERIMENTAL PROCEDURES
GSK2324 was dissolved in water and administered to mice via intraperitoneal
(i.p.) injection at 30 mg/kg body weight (mpk) unless otherwise stated. In ex-
periments where GW4064 and GSK2324 were compared, agonists were dis-
solved in water containing 0.5% Tween 80, and mice were treated once daily
with either drug or vehicle alone at 60 mpk for 3 days via i.p. injection. Unless
otherwise stated, mice were fasted for 4–6 hr after the last treatment with FXR
agonists prior to removal of tissues. All animal experiments were carried out
according to NIH guidelines and were approved by the Office of Animal
Research Oversight (OARO) at UCLA. For MafG ASO studies, male 12-
week-old C57BL/6 mice (Jackson Laboratory) were dosed once with either
control or MafG ASO at 100 mpk, and 3 days later, mice were fasted overnight
and livers collected the following morning (9–11 a.m.). All adenoviruses were
prepared in BSL2 category facilities. Briefly, cDNAs for mouse MafG, Crip2,
and Zfp385a were cloned from whole-liver cDNA into pAdTrack CMV plasmid
and prepared as described in Bennett et al. (2013). For animal experiments,
13 109 plaque-forming units (PFU) were used, and tissueswere collected after
5–7 days, and for cell culture studies, a moi of 1–10 was used, and cells were
harvested for analysis after 24–48 hr. For gene expression analysis, RNA was
isolated using QIAZOL according to the manufacturer’s instructions (QIAGEN)
and rDNaseI treated before cDNA was synthesized (Life Technologies). qRT-
PCR analysis was carried out using primers described in Table S1, and gene
expression data were normalized to Tbp and/or 36B4/Rplp0. Western blotting
analysis was carried out from liver samples (approximately 100 mg of tissue)
homogenized in 1 ml of RIPA buffer supplemented with protease inhibitor
complex (Roche). Protein was quantified using the BCA assay (Thermo Fisher
Scientific), and 10–30 mg of protein was loaded on pre-cast gels (Bio-Rad).
Protein was transferred to PVDF membranes (Millipore), probed with anti-
bodies described in the Supplemental Experimental Procedures, and detected
with ECL reagent (Sigma) or ECL Prime (GE Healthcare) using a GE Image
Quant LAS 4000 detection system (GE Healthcare). Bile acid analysis was
carried out from biliary material by HPLC, and the major taurine-conjugated
species were detected by measuring absorbance measured at 205 nm and
compared to known bile acid standards. Total bile acids were measured in
liver, intestine, and gall bladder as described in the Supplemental Experi-
mental Procedures. For promoter-reporter studies, mouse MafG promoter
(2 kb), Cyp8b1 promoter (0.5 kb), and Cyp7b1 promoter (1 kb) were amplified
from mouse genomic DNA (C57BL/6) using KAPA HiFi polymerase (Kapa) andc.
cloned into pGL4.10[luc2] plasmid (Promega). Luciferase reporter constructs
were transfected using Fugene HD (Promega) (n = 6 wells per condition) ac-
cording to manufacturer’s instructions into human HepG2 or Hep3B cells
(ATCC) and plated onto 48-well dishes. For MafG ChIP analysis, mice were
treated with Ad-BLRP or Ad-BLRP-MafG for 5 days. Livers were fixed in
PBS containing 1% formaldehyde, nuclei were isolated, and chromatin was
sheared by sonication for 25–30 cycles using BioRuptor Twin (Daigenode)
and immunoprecipitated using a BLRP antibody (Avi-tag, GeneScript) as
described in the Supplemental Experimental Procedures. For ChIP-seq,
immunoprecipitated DNA was used for library preparation (Kapa Biosystems)
and sequenced by the UCLA UNG Core. Analysis of ChIP- and RNA-seq, as
well as microarray analysis, is described in the Supplemental Experimental
Procedures.
Statistics
All bars shown are mean ± SEM. The comparison of different groups was
carried out with Student’s t test, one- and two-way ANOVA, and differences
under p < 0.05 were considered statistically significant (*p < 0.05, **p < 0.01,
***p < 0.001, and different letters indicate at least p < 0.05).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and two tables and can be found with this article online at http://
dx.doi.org/10.1016/j.cmet.2015.01.007.
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